Microfluidic device (1) comprising at least one fluid channel (2) comprising at least one inlet (3), wherein said at least one fluid channel (2) is fluidly connected to a first sensor (4) downstream of said at least one fluid inlet (3), wherein the first sensor (4) comprises at least one sensor cathode (5) and at least one sensor anode (6) formed on an essentially electrically isolating substrate (7), wherein the sensor cathode (5) and the sensor anode (6) are spaced apart by a gap (8) formed on the electrically isolating substrate (7), and wherein at least one analyte capturing molecule (9) is immobilized in the gap (8) on the substrate (7), wherein the at least one capturing molecule (9) is adapted to capture at least one analyte (10) of a fluid sample introduced into the inlet (3) and transported to the first sensor (4).

The present application provides a novel coronavirus antibody detection kit based on magnetic particle chemiluminescence. The detection kit includes: streptavidin magnetic particles, biotin-labeled novel coronavirus antigens, an acridine sulfonamide-labeled secondary antibody, a sample diluent and a quality control material; wherein the biotin-labeled novel coronavirus antigens include a recombinant nucleocapsid protein and a recombinant spike protein S1. The sample to be tested, the biotin-labeled antigens and the streptavidin magnetic particles are mixed, incubated and washed, and then the acridine sulfonamide-labeled antibody is added to form a magnetic particle-streptavidin-biotin-antigen-novel coronavirus antibody-secondary antibody complex, and then the luminous intensity is detected to qualitatively determine the sample to be tested.

Devices and methods for the detection of an analyte, e.g, from exhaled breath or air are provided. A sensor includes a polymer layer molecularly imprinted for the analyte, a metal layer, and an electrocatalytic layer disposed between the polymer layer and the metal layer. The electrocatalytic layer is functionalized with at least one chemical compound that provides for noncovalent interaction with the analyte. The sensor further includes electrodes in operative arrangement with the polymer layer and configured to provide a signal indicative of a resistance. A change in resistance of the device can indicate the presence of the analyte in the sample.

Antibodies against a virus can be detected in a sample using at least one reagent comprising at least one capture molecule immobilized to a particle, which reagent in the presence of such antibodies forms an anti-virus antibody-capture molecule complex, wherein the presence of said complex is qualitatively, quantitatively or semi-quantitatively determined by measuring a signal generated by said complex, said particle is a nanoparticle and said capture molecule is immobilized to said nanoparticle simultaneously with a co-molecule which is smaller than said capture molecule. When the capture molecule is a virus epitope, the co-molecule preferably has a molecular weight in the range of 50-1500 Da, wherein said co-molecules when immobilized on said nanoparticle separate the capture molecules so that an average distance between two adjacent capture molecules is greater than a distance between the antigen binding sites of the anti-virus antibody to be detected.

The present invention includes compositions and methods for detecting the presence of: a coronavirus or an immune response to a coronavirus infection including T cells responsive to one or more coronavirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from SEQ ID NO: 1 to 1126, subsequences, portions, homologues, variants or derivatives; a fusion protein comprising one or more amino acid sequences selected from SEQ ID NO: 1 to 1126; a pool of peptides or proteins selected from the amino acid sequences set forth in SEQ ID NO: 1 to 1126; or a polynucleotide that encodes one or more peptides or proteins, comprising, consisting of, or consisting essentially of an amino acid sequence selected from SEQ ID NO: 1 to 1126, subsequences, portions, homologues, variants or derivatives. The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

Disclosed herein are reagents for use in antibody profiling platforms, such as biopanning and Digital Serology, specifically for eptiope motifs directed to SARS-CoV-2. Also disclosed herein are kits, method of manufacturing, and methods of using the same.

Protein biosensors and methods of using these sensors to detect anti-SARS-CoV-2 patient antibodies (Abs) in a solution-based, rapid, and quantitative COVID-19 serological assay are provided. In certain aspects, the sensors each comprise a first fusion protein that comprises a first SARS-CoV-2 viral protein and a first peptide fragment of a split reporter protein, and a second fusion protein that comprises a second fusion protein that comprises a second SARS-CoV-2 viral protein domain and a second peptide fragment of the split reporter protein. Only if the test sample comprise SARS-CoV- antibodies, the first and second peptide fragments associate to produce an enzymatically active reporter protein.

Provided herein are binding proteins recognizing SARS-CoV-2 antigens and uses thereof.

The present disclosure presents nanostructure-based localized surface plasmon resonance systems and related methods. In this regard, a method comprises applying a body fluid sample to a metal surface of the nanostructure-based LSPR biosensor with linker, intermediate, and capture/probe antibodies; illuminating the metal surface of the nanostructure-based LSPR biosensor with the monochromatic, broadband, or laser light; measuring an intensity or spectrum of absorbed, reflected, transmitted, or scattered exiting light from the nanostructure-based LSPR biosensor having the body fluid sample and comparing the measured intensity or spectrum with a reference intensity; detecting a spectral shift of exiting light from the nanostructure-based LSPR biosensor having the body fluid sample; and signaling that the body fluid sample is positive for a presence of a particular biomaterial in response to detecting the spectral shift of the exiting light, wherein the biomaterial has binded or adsorbed to the metal surface of the nanostructure-based LSPR biosensor.

The disclosure herein relates to novel antibodies and antigen binding fragments that are used in the treatment, prevention and diagnosis of COVID-19, the disease caused by SARS-CoV-2. The complete polypeptide and nucleic acid consensus sequences of the antibodies and antigen binding fragments disclosed herein are reconstructed in silico.